



DEPOSITARY RECEIPTS

NEW DR ANNOUNCEMENT

November 16, 2015

Advanced Accelerator Applications S.A.

Advanced Accelerator Applications is a radiopharmaceutical company based in France. The Company is engaged in the development, production and commercialization of molecular nuclear medicine, diagnostic and therapeutic products in the fields of oncology (cancer), neurology, cardiology and infectious & inflammatory diseases. The Company's key product candidates in clinical development are Lu-DOTATATE (Lutathera), Ga68-DOTATATE/TOC (Somakit) and Annexin V-128. Lu-DOTATATE is a Molecular Nuclear Therapy product candidate. The Company operates in France, Italy, Spain, U.K., Portugal, Germany, Switzerland, Poland, Israel, U.S.A. and Canada while its distribution network covers more than 30 countries.

Effective Date:	November 16, 2015
Country of Incorporation:	France
Exchange:	NASDAQ Stock Market
Type of ADR Program:	Sponsored - Level III
Ticker Symbol:	AAAP
CUSIP Number:	00790T100
Ratio (DR:ORD):	1 : 2
Underlying Share Description:	Ordinary
Industry Classification:	Pharma. & Biotech.
Custodian(s) :	BNP Paribas Securities Services

To learn more about ADRs and issuer programs, please call our marketing desks:

New York

Ravi Davis
 Adrdesk@bnymellon.com
 Tel: 212 815 2267

Hong Kong

Herston Powers
 Vice President
 herston.powers@bnymellon.com
 Tel: 65 6432 0281

London

Jacek Jankowski
 DR Broker Liaison
 jacek.jankowski@bnymellon.com
 Tel: 442071637427

Depository Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon and are subject to investment risks including possible loss of principal amount invested.

This announcement and the information contained herein is provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this information. We provide no advice or recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. An offering is made by means of a prospectus only. BNY Mellon is regulated by the FSA.